Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887141 | 1.00 | EPHX1 (0.38) | EPHX1TDP1ALDH1A1TSHRCHRNB2 | |
| SCHEMBL552809 | 0.83 | TDP1 (0.38) | TDP1ALDH1A1TSHRCYP2D6CA12 | |
| SCHEMBL19821956 | 0.83 | CTSK (0.33) | TDP1ALDH1A1TSHRCA12CA1 | |
| SCHEMBL7819855 | 0.79 | ALDH1A1 (0.35) | EPHX1TDP1ALDH1A1TSHRCA12 | |
| SCHEMBL6175769 | 0.79 | ALDH1A1 (0.35) | TDP1ALDH1A1TSHRCA12CA1 | |
| SCHEMBL28260830 | 0.79 | EPHX1 (0.36) | EPHX1TDP1ALDH1A1TSHRCHRNB2 | |
| SCHEMBL8404812 | 0.79 | EPHX1 (0.38) | EPHX1TDP1ALDH1A1TSHRCHRNB2 | |
| SCHEMBL3342222 | 0.79 | TDP1 (0.46) | EPHX1TDP1ALDH1A1TSHRCA12 | |
| SCHEMBL28996704 | 0.79 | EPHX1 (0.46) | EPHX1TDP1ALDH1A1TSHRHSD17B10 | |
| Propane SCHEMBL28996705 | 0.78 | CA1 (0.44) | EPHX1TDP1ALDH1A1CYP2D6CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-3737418-B1 | POLYMERS WITH RIGID SPACING GROUPS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | SONY GROUP CORP (JP) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024020164-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11773266-B2 | Polymer, molded body, foam, resin composition, and production method for polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-10-03 | — | — | US | disclosed |
| US-20230129965-A1 | HYDROPHILIC AND OLEOPHOBIC POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4005600-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | Yale University (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-113754589-A | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-107311935-B | Compositions, methods, and systems for synthesis and use of contrast agents | 蓝瑟斯医学影像公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-113398126-A | Use of 4' -deferthionin analogues | 佛罗里达大学研究基金会 | 2021-09-17 | — | — | CN | disclosed |
| WO-2020210689-A1 | PROGRAMMABLE POLYMERIC DRUGS | SONY CORPORATION (JP) | 2020-10-15 | — | — | WO | disclosed |
| US-6586414-B2 | Administering pyridoxal-5'-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues thereof; treatment of strokes | MEDICURE INTERNATIONAL INC. (BB) | 2003-07-01 | — | — | US | disclosed |
| US-20030114424-A1 | Treatment of cerebrovascular disease | MEDICURE INTERNATIONAL INC. (BB) | 2003-06-19 | — | — | US | disclosed |
| EP-1278526-A2 | TREATMENT OF CEREBROVASCULAR DISEASE | Medicure International Inc. (BB) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002028835-A1 | BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-04-11 | — | — | WO | disclosed |
| US-6339085-B1 | FOR THERAPY OF HYPERTROPHY, HYPERTENSION, CONGESTIVE HEART FAILURE, MYOCARDIAL ISCHEMIA, ARRHYTHMIA, HEART FAILURE SUBSEQUENT TO MYOCARDIAL INFARCTION, MYOCARDIAL INFARCTION, ISCHEMIA REPERFUSION INJURY, BLOOD COAGULATION | THE UNIVERSITY OF MANITOBA (CA) | 2002-01-15 | — | — | US | disclosed |
| EP-1169322-A1 | PYRIDOXAL ANALOGUES FOR VITAMIN B-6 DISORDERS | Medicure Inc. (CA) | 2002-01-09 | — | — | EP | disclosed |
| US-20010056081-A1 | Treatment of cerebrovascular disease | MEDICURE INTERNATIONAL INC. (CA) | 2001-12-27 | — | — | US | disclosed |
| US-20010031770-A1 | Pyridoxal analogues and methods of treatment | MEDICURE INC. (CA) | 2001-10-18 | — | — | US | disclosed |
| WO-2001072309-A2 | TREATMENT OF CEREBROVASCULAR DISEASE | MEDICURE INTERNATIONAL INC. (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2000053606-A1 | PYRIDOXAL ANALOGUES FOR VITAMIN B-6 DISORDERS | MEDICURE INC. (CA) | 2000-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | EPHX1 590/4885TDP1 1160/4885ALDH1A1 98/4885 |
| US-20010056081-A1 | Treatment of cerebrovascular disease | PNPO, PLPBP, VNN1 | EPHX1 555/4885TDP1 1245/4885ALDH1A1 1352/4885 |
| US-20010031770-A1 | Pyridoxal analogues and methods of treatment | PNPO, PDXK, PLPBP | EPHX1 772/4885TDP1 1896/4885ALDH1A1 1143/4885 |
| US-20030114424-A1 | Treatment of cerebrovascular disease | PNPO, PLPBP, VNN1 | EPHX1 555/4885TDP1 1245/4885ALDH1A1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.